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        Recent  advances  suggest  that  telomerase  is
associated  with  cellular  immortality  which  is  a
hallmark of cancer.
TELOMERES
Human telomeres contain an array of tandem DNA
repeats.   We   share   the   telomeric   sequence
(TTAGGG)n  with  all  other  vertebrates.  Human
chromosomes  end  in  several  kilobases  of  telomeric
repeat DNA. These are oriented so that the guanine
(G)-rich   strand   runs   out   to   the   3’   end   of   the
chromosome. Despite their monotonous sequence,
telomeres   fulfil   important   functions.   First,   they
hide natural chromosome end from factors acting on
DNA termini unlike broken chromosome ends which
either   get   degraded   or   fuse   to   other   DNA.
Telomeres  are  resistant  to  exonucleases  and  ligases.
They also escape detection by the DNA damage
checkpoints.  The  termini  of  natural  chromosome
ends   are   probably   concealed   by   a   complex   of
specialized   proteins   that   bind   telomeric   DNA.
Telomere  length  is  maintained  by  a  balance  between
the    telomeres-lengthening    process    ( e.g.,
telomerase)[1]  and  the  telomeres-shortening  process
(end   replication).   The   inability   of   the   DNA   to
completely    replicate    chromosome    termini
(telomeres)  leads  to  the  progressive  shortening  of
chromosomes upon continuous cell division. The
shortening  can  ultimately  lead  to  loss  of  telomeric
function and chromosomal destabilization. A DNA
polymerase   called   telomerase   is   required   to
overcome the end replication.
TELOMERASE
Human telomerase is a ribonucleoprotein (RNP)
composed  of  an  essential  RNA  and  a  few  proteins.
It   synthesizes   the   G-rich   tandem   repeats   that
comprise   telomeres  [(TTAGGG)150-2000   in   humans]
using  a  template  on  the  RNA  that  is   complementary
to  the  telomeric  repeat.  By  adding  hexameric
(TTAGGG) repeats to the telomeric ends of the
chromosomes, the continued erosion of telomeres is
compensated. The enzyme is expressed in embryonic
cell   and   in   adult   male   germ   line   cells[2],   but   is
undetectable in normal somatic cells except for
proliferative   cells   of   renewable   tissues   (e.g.
haemopoetic  stem  cells  and  activated  lymphocytes,
basal  cells  of  the  epidermis  and  intestinal  crypt
cells).   In   normal   somatic   cells,   progressive
shortening   of   telomere   leads   to   a   limited   replicative
capacity.   Recently   more   direct   evidence   has   been
found in the role of telomere short ening in aging[3].
TELOMERIC PROTEINS
Telomeres are essential for the maintenance of
chromosomes.     Another    group    of    important
regulators  for  telomere  function  is  the  telomere
binding  proteins[4].  They  were  originally   described
as  proteins,  binding  specifically  to  telomere  DNA
(for example, to the hexameric repeat). The RAP 1
protein in budding yeasts and the TRF1 protein in
mammalian   cells   are   examples   of   this   class   of
proteins[5].  Another  type  of  proteins  interacts  with
the    telomere    DNA-binding   protein/protein-
interactions  and  comprises  a  large  functional
chromosome   domain  called  the  “telosome”[6].
Examples  are  the  SIR  3/SIR 4  proteins  and  the RIF
1  protein  in  saccharomyces  cerevisiae[6].  These
proteins  associate  with  the  RAP 1  telomere  DNA-
binding  protein  and  function  to  establish  telomere
silencing  effect  and  regulate  telomere  length
respectively.   Some   of   these   proteins   negatively
regulate   telomere   length,   probably   by   inhibiting
telome  rase  activity[7].  Therefore,  the  length  and
function  of  telomere  are  not   determined  simply  by
the   balance   between   the   total   number   of   cell
divisions and  telomerase activity.
TELOMERASE IN MALIGNANCY
While   all   of   the   steps   leading   to   cancer   are   still
unknown,   progression   to   a   cancerous   state   does
require   the   accumulation   of   a   series   of   genetic
alterations   similar   to   those   found   in   the   in   vitro
models     of     carcinogenesis.     For     instance,
hyperproliferation   occurs   due   to   the   failure   to
respond   to   growth   inhibitory   signals   and   the
functions allowing cells to divide in the absence of
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specific   growth   stimulatory   signals.   Additional
mutations  must  take  place  for  cell  to  progress  to
invasive  and  then  metastatic  states.  To  the  extent
that each of these conditions represents a mutational
event,  a  clonal  expansion  of  the  cell  is  required  for
the occurrence of mutation. Some of these changes
involve recessive  events  where  an  initial  clonal
expansion  of  cell  containing  the  original  mutation
must  be  followed  by  a  second  clonal  expansion  with
the  remaining  wild  type  allele  eliminated.  If  this
series  of  events  require  a  greater  number  of  cell
divisions  than  permitted  for  normal  cells,  potential
tumor   cells   must   incorporate   a   mechanism   to
overcome  this  limitation.  It  appears  that  in  many
cases,  the  reactivation  of  telomerase  serves  this
purpose, yet it may not be the only mechanism. The
presence  of  telomerase  activity  only  indicates  that
the  cell  has  the  ability  to  inactivate  the  telomeric
“clock”  that  limits  the  proliferative  capacity  of  normal
somatic cells[8]. The presence of telomerase activity in
a cell implies very little about malignancy, but only reflects
its  potentially  immortal  state.  Cell  immortality  only
gives  the  cells  the  proliferative  capacity  to  accumulate
the  necessary  mutations  to  become  malignant.  As
cancer is diverse, some tumors may need only a few
mutations in order to become malignant and may not
exhaust the normal limits of proliferation before they
cause disease. These types of cancer would be expected
to be both immortal and negative for telomerase activity.
As  proliferative  limits  can  be  exceeded  at  any  time
during  cancer progression,  the  reactivation  of
telomerase  would  be  expected  to occur   early  in
tumors arising from cells near the limits of their
proliferative capacity and late in tumors arising from cells
with  long  telomeres.  In  some   cases  of  tumors
arising  from   telomerase  positive  stem  cells,  the
initiating  cells   may  already  be  competent  to  be
immortal.
         The fact that almost all cancers have telomerase
activity,   despite   their   shortened   telomeres[2,9,10]
indicate  that  there  is  an  intense  selective  pressure
for telomerase activation with the progression of
malignancy.  Indirect  support  for  this  view  comes
from  the  observations  that  benign  or  precancerous
lesions (e.g. colonic polyps or adenoma; prostate
hyperplasia  and  fibroids)  are  telomerase  silent[9].  As
telomeres  shorten,  accumulated  mutations  in  other
genes  such  as  the  genes  encoding  p53  and  RB
(retinoblastoma protein) would result in genomic
instability,  an  extended  life-span  and  progressive
erosion  of  telomeres[11,12]. At  this  point,  end  to  end
chromosome  fusions  are  frequently  observed,
concomitantly  with  critically  shortened  telomeres.
These  events  could  contribute  to  the  loss  of
heterozygosity  and  the  expression  of  recessive
mutations,  which  would  result  in  the  reactivation  of
telomerase  and  stabilization  of  telomere  length,  as
well  as  fixation  of  the  additional  mutations  required
for invasiveness and metastasis.
Telomerase activity in colorectal cancer
The  colorectal  adenoma-carcinoma  sequence  is  one
of the best characterized models for multistep
tumorigenesis.  Progression  may  be  extremely  slow
due to the high ratio of adenomas to cancers. Telomere
shortening  is  observed  in  colorectal  adenomas  and
carcinomas[13].  Recent  studies  have  demonstrated
that  although  most  adenomas  lack  telomerase  activity,
the  majority  of  colorectal  cancers   express   this
enzyme[2,9]   and   contain   detectable   telomerase
activity   regardless   of   underlying   phenotype   (77%
of   hereditary   nonpolyposis   colorectal   cancers;
81%   of   sporadic   tumors,   88%   with   mutator
phenotypes and 75% without mutator phenotypes)[14].
Therefore, telomerase expression appears to be
commonly   acquired   in   the   progression   of   both
mutator phenotype and sporadic colorectal cancers.
These   findings   in   colorectal   cancer   are   consistent
with   the   telomere   hypothesis.   However   a   minority
of   colorectal   cancers   lack   detectable   telomerase
activity[8] and other alternatives remain[10].
Telomerase activity in gastric cancer
The   pattern   of   multiple   gene   changes   in   gastric
cancer   varies   with   the   histological   type ,   well
differentiated    or    intestinal    type    and    poorly
differentiated  or  diffuse  type.  However,  activation
of   telomerase,   which    is    responsible   for   cell
immortality  is  the   most  common  fundamental  event
in  gastrointestinal  cancer[2,9,15].  Human  telomerase
RNA  (hTR)  is   expressed  in  pre-crisis  cell  lines  and
non-neoplastic  tissues,  as  well  as  in  immortalized
cell  lines  or  tumor  specimens  and  the  expression
level   is   not   correlated   with   that   of   telomerase
activity[16].  Telomerase  activity  is  detected  in  85%-
88%    of    gastric    carcinomatous     tissues[16,17].
Although  all  tumor  specimens  and  non-cancerous
mucosa   expressed   various   levels   of   hTR,   81%
expressed  hTR  at  a  higher  level  in  the  tumor  than
that in the corresponding mucosa. All the 8 gastric
carcinoma  cell  lines  also  expressed  hTR  at  higher
levels. Thirty-five percent of non-cancerous mucosa
showed   telomera   se   activity   and   all   of   them
contained   intestinal   metaplasia.   The   degree   of  -
Helicobacter  pylori-infection  increased  in  parallel
with  the  level  of  hTR  expression  and  telomerase
positivity[17]. These results suggest that  Helicobacter
pylori infection may be a strong trigger for hTR
overexpression   in   intest   inalmetaplasia,   and   this
may  lead  to  telomerase  reactivation.  Tumors  with
telom  erase  activity  were  generally  large  in  size  with
a  high  frequency  of  lymph  node  metastasis.  In  the
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tumors  without  detectable  telomerase  activity,  80%
were  early  stage  gastric  cancer.  In  gastric  cancer,
telomerase  activation  may  occur  as  a  late  event  of
cancer  progression  as  demonstrated  previously  in
non-small   cell   lung   cancer[18].   Moreover,   the
patients  with  telomerase-positive  tumors  showed
poorer   prognosis   than   those   with   telomerase-
negative tumors, indicating that telomerase-positive
gastric cancers may have more malignant potential.
Telomerase  activity  and  telomere  length  in
HCC and CLD
It  is  well  known  that  almost  all  HCC  are  preceded
by  chronic  hepatitis  (CH)  and/or  liver   cirrhosis
(LC).  These  two  conditions  are  regenerative  lesions
in  response  to  repeated  liver  damage  induced  by
hepatitis  B  or  C  virus  (HBV/HCV)  infection  or
other  factors.  However,  the  role  of  these  lesions  in
HCC carcinogenesis remains unclear, except for the
possible involvement of transforming activity of the
HBVX   protein[19].   There   was   progressive
shortening  of  telomeres  during  hepatocellular
carcinogenesis  from  normal  liver  to  CH  to  LC  to
HCC.  The  average  telomere  length  of  HCC  was
significantly  and  consistently  shorter  than  that  of
adjacent   CH   or   LC[20].   The   possible   role   of
telomere  shortening  in  regenerative,  noncancerous
liver  lesions  (CH  and  LC)  is  that  it  may  eventually
lead to reactivation of telomerase, which may then
contribute  to  the  malignant  conversion  to  HCC.
Thus  telomere  shortening  in  the  regenerative  lesions
is  not  merely  representative  of  cellular  aging,  but
may also be a prerequisite for the development of
malignancy.  A  subpopulation  of  cells  in  such  lesions
with  telomeres  shortened  to  a  critical  length,  may
suffer   genetic   changes   due   to   chromosome
instability[3].  These  genetic  changes  would  make
most  cells  senescent,  but  allow  a  small  number  of
cells   to   undergo   additional   mutations,   including
those  activating  or  upregulating  telomerase  which
then  clonally  develop  into  immortal  cancer  cells.
Telomere length was shorter in chronic liver diseases
compared   with   that   in   normal   liver[21].   This
indicates  that  senescence  of  hepatocytes  occurs  in
patients  with  advanced  liver  diseases  probably  as  a
result   of   degenerati   on   and   the   following
regeneration    of   hepatocytes.   Although   the
mechanisms of car cinogenesis in type C chronic liver
diseases  are  not  known,  the  incidence  of  HCC
increases as the stage of the disease advances[22].
Telomerase activity  was measured in various tissues
and  cell  lines[2,9,15]  including  HCC[23]   and   was
shown   to   be   positive   in   85%-100%   of   various
malignant  tissues  and  negative  in  almost  all  non-
malignant tissues, except for reproductive and
haemopoietic   cells.   Telomerase   activity   was
negative   in   15%   of   the   HCC   specimens[21].   One
possible  reason  for  this  undetectability  might  be
false  negativity  due  to  the  possible  presence  of
polymerase   chain   reaction   inhibitor[24 ].   However
the presence of such inhibitor was not confirmed. In
another previous report the telomerase activity in
malignant  tissue  was  not  positive[23 ] and  a  recent
report has clearly shown that several tumor cell lines
keep   their   telomere   length   without   telomerase
activity[25].   Consequently,   some   unidentified
mechanism  for  restoring  the  telomere  length  must
exist[26].  Thus,  it  seems  that  a  small  number  of  HCC
do not possess telomerase activity.
TELOMERASE—A TARGET FOR CANCER TREATMENT
Telomeres  and  telomerase  play  a  role  in  signalling
cellular  senescence  and  in  the  progression  of
tumorigenesis,   anticancer   therapies   could   be
targeted  at  telomerase.  The  gene  encoding   the
human  RNA  component  of  telomerase  has  been
cloned[27]. Following strategies are available.
        A:   Obstructing   telomerase   RNA   activity
through an antisense oligonucleotide targeted to the
template   region.   Encouragingly,   expression   of
antisense  to  hTR  in  an  immortal  telomerase-
expressing cell line resulted in a gradual reduction of
telomere length, leading to death of the cells[27].
         B: Generation of mutant telomerase RNA.
       C: Protein components of telomerase present
another viable target for inhibition.
         Telomerase   inhibitors   may   thus   provide   an
effective  cancer  therapy  with  no  side  effects  of
general  cancer  therapy  in  normal  somatic  cells  that
lack  telomerase  expression.  A  future  treatment
regimen  may  include  surgical  removal  of  the  tumor,
followed by combined antitelomerase therapy with
conventional  radiation  and/or  chemotherapies.   As
most  cancer  cells  have  much  shorter  telomeres  than
the  stem  cells  of  renewal  tissues,  the  treatment
period  could  be  designed  to  end  prior  to  stem  cell
attrition  by  preserving  the  replicative  abilities  to
divide  stem  cells.  Thus  the  effects  of  inhibiting
telomerase  activity  are  likely  to  eliminate  the  cancer
cells  long  before  telomere  lengths  in  stem  cells
become limited.
CONCLUSION
Clearly,   telomerase   regulation   is   complex   and
further   studies   are   needed   on   the   multiple
mechanisms  regulating  telomerase  activity  with
respect  to  the  addition  of  telomeric  repeats  and  its
relation  to  cellular  growth.  Telomerase  fulfills  many
of  the  criteria  for  an  ideal  cancer  target  and  has  a
nearly  ideal  developmental  and  tissue-expression
pattern,   what   remains   is   to   show   that   tumors
require   telomerase   for   growth   and   that   loss   of
telomerase function will be clinically useful.
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